Peptide Hydrogel CEST Contrast Agents for Safe Multi-Color MRI
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current magnetic resonance (MR) contrast agents, particularly those containing paramagnetic metals, pose safety concerns due to toxicity and limited ability to provide multi-color contrast, necessitating the development of non-metallic, biodegradable compounds for safe and efficient multi-modal imaging.
Innovation Solution
A peptide-based hydrogel CEST agent is developed, incorporating lysine, arginine, serine, threonine, histidine, tryptophan, and unnatural amino acids with heterocyclic protons, capable of producing chemical shifts and exchange rates suitable for generating CEST contrast in MR imaging, allowing for safe and simultaneous tracking of multiple entities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If paramagnetic metal-based contrast agents are used, then strong signal enhancement is achieved, but toxicity and safety concerns arise
Solution Approach 1:
The patent extracts and removes the harmful paramagnetic metal components from contrast agents, replacing them with non-metallic diamagnetic compounds that maintain CEST contrast capabilities without the associated toxicity concerns
Solution Approach 2:
The patent employs biodegradable peptide-based hydrogels as temporary, disposable contrast agents that safely degrade in the body after serving their imaging function, eliminating long-term metal accumulation risks
2Reliability
If paramagnetic metal-based contrast agents are used, then one type of contrast is provided, but multi-color detection capability is lost
Solution Approach 1:
The patent designs peptide-based CEST agents with multiple exchangeable proton pools at different chemical shifts, enabling a single agent to provide multi-color detection capabilities for simultaneously tracking multiple biological processes or agents
Solution Approach 2:
The patent utilizes variations in chemical shift parameters of exchangeable protons to create distinct CEST contrast signatures, allowing differentiation and simultaneous detection of multiple targets through frequency-specific saturation transfer
3Reliability
If high doses of contrast agents are administered, then signal enhancement is improved, but safety risks increase
Solution Approach 1:
The patent exploits the high sensitivity of CEST agents, which can detect micromolar concentrations of polypeptide gene carriers and close to nanomolar concentrations of polynucleotides, allowing effective imaging at very low doses that minimize safety risks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-based hydrogel provides effective, biocompatible CEST contrast for MR imaging, overcoming toxicity issues and enabling multi-color detection, thereby enhancing imaging capabilities and safety by using non-metallic, biodegradable compounds.
Implementation Method 1
A peptide-based hydrogel CEST agent is developed, incorporating lysine, arginine, serine, threonine, histidine, tryptophan, and unnatural amino acids with heterocyclic protons, capable of producing chemical shifts and exchange rates suitable for generating CEST contrast in MR imaging
Data Source
AI summary
The present invention provides novel hydrogels through peptides, which are designed to self-assemble and produce magnetic resonance (MR) contrast through chemical exchange saturation transfer (CEST). The location and integrity of these gels could consequently be tracked using MR imaging. The self-assembly of the peptides into hydrogels can be brought about by a change in pH, ionic strength, temperature, and concentration of ions.